![Gianfranco Gilardi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gianfranco Gilardi
Corporate Officer/Principal bij The Royal Society of Chemistry
Profiel
Gianfranco Gilardi is the founder of NanoBioDesign Ltd., which was founded in 2001.
He held the title of Chief Scientific Officer from 2010 to 2012.
Currently, Dr. Gilardi holds positions at The Royal Society of Chemistry as a Member and at the University of Turin as a Professor.
Actieve functies van Gianfranco Gilardi
Bedrijven | Functie | Begin |
---|---|---|
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Corporate Officer/Principal | - |
University of Turin | Corporate Officer/Principal | - |
Eerdere bekende functies van Gianfranco Gilardi
Bedrijven | Functie | Einde |
---|---|---|
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Oprichter | 06-12-2012 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Commercial Services |
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Health Technology |